This one-hour, on-demand, journal article-based activity discusses original research on naloxone ​dosing for prevention of return to use in people with opioid use disorder. It examines the relationship between plasma levels of extended-release naltrexone (XR-NTX) and subjective responses to opioids in individuals with opioid use disorder (OUD), highlighting the importance of maintaining therapeutic naltrexone (NTX) levels.

This 16-hour, on-demand course is the essential primer for physicians preparing for the addiction medicine examination and also serves to increase other healthcare professionals' knowledge of addiction.

This 60-minute, on-demand session from the ASAM 2023 Review Course provides an understanding of key principles such as tolerance, dependence, hyperalgesia, pharmacokinetics, and pharmacodynamics while also discussing applications and limitations including interpretation pitfalls of screening and confirmatory urine drug tests.

This 60-minute, on-demand session from the ASAM 2023 Review Course provides an overview of the history of opioid use and opioid regulation, explores the neurobiology and pharmacology of opioids, and reviews treatment options for opioid use disorder and opioid withdrawal.

This 30-minute, on-demand session from the ASAM 2023 Review Course covers a diverse group of substances including hallucinogens, dissociatives, inhalants, and steroids as well as the physiological effects, epidemiology, and treatment options.

This 72.5 hour on-demand conference includes over 70 sessions highlighting best practices and the latest science, research, and innovations in addiction medicine from leading experts in the field.

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses the evolution of cannabis products including delta-8 THC and other novel cannabinoids available in the United States with a focus on products and preparations available today, their legal status, and methods of consumption.

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses the pharmacology and clinical/preclinical evidence for the use of psychedelics and psychedelic-assisted therapy for various substance use disorder (SUDs).

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses multiple strategies to expand the pharmacopeia of alcohol use disorder (AUD) therapies, including repurposing of medications that are already FDA-approved, and conducting lab-based, experimental early-phase clinical trials to provide proof-of-concept evidence for the new compounds.

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses the use of ketamine to treat and/or prevent buprenorphine-precipitated opioid withdrawal in the emergency department and outpatient settings.